14 Nov Long-Acting Inhalable Drugs for Chronic Obstructive Pulmonary Disease
Posted at 10:44h
in
Long-Acting Inhalable Drugs for Chronic Obstructive Pulmonary Disease
HC0086
Overview
Background
- Chronic obstructive pulmonary disease (COPD) affects millions of Canadians and adults around the world.
- Acute events in COPD, called exacerbations, are associated with significant morbidity, mortality, and health care expenditures. While these acute exacerbations can be treated with short-acting inhalers, oral corticosteroids, and antibiotics, daily use of maintenance inhalers can help reduce their frequency and severity.
- The three general categories of maintenance inhalers include long-acting β2 agonists (LABAs) and long-acting muscarinic antagonists (LAMAs), and inhaled corticosteroids (ICS).
Objectives
- Part 1 objective (using CIHI data): To describe initial use of 6 long-acting inhalable COPD therapies (LABA monotherapy, LAMA monotherapy, LABA/LAMA, LABA/ICS, LAMA/ICS, and LABA/LAMA/ICS combination therapies).
- Part 2 objectives (using CNODES provincial data source):
- To describe temporal trends and characteristics of patients initiating treatment with 6 long-acting inhalable COPD therapies in Canada between 2012 and 2024 stratified into 2 eras, 2012 to 2017 and 2018 to 2024.
- To describe treatment evolution among patients within each of the initiation cohorts and the prevalence of COPD exacerbations as treatment evolves, stratified into the same 2 eras.